Adage Capital Partners
ADCT icon

Adage Capital Partners’s ADC Therapeutics ADCT Stock Holding History

Adage Capital Partners’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,000,000
Closed -$4.49M – 862
2024
Q1 		$4.49M Buy
+1,000,000
New +$3.69M 0.01% 707

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Adage Capital Partners's ADCT Position: Q2 2024 in Review

Adage Capital Partners sold out of ADC Therapeutics (ADCT) in Q2 2024, closing a stake of 1,000,000 shares — an estimated $4.49M sold.

Adage Capital Partners first reported a position in ADCT in Q1 2024 and held it in 1 quarter. The position peaked at $4.49M in Q1 2024. 74 funds tracked by Wall St. Rank hold ADCT as of Q2 2024.

  • Adage Capital Partners reported no remaining ADC Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Adage Capital Partners sold 1,000,000 ADC Therapeutics shares in Q2 2024, an estimated $4.49M.
  • Adage Capital Partners first reported a position in ADC Therapeutics in Q1 2024 and held it in 1 quarter.
  • Adage Capital Partners's ADC Therapeutics position peaked at $4.49M in Q1 2024.
  • 74 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2024.

Based on Adage Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.